NASDAQ NMS - GLOBAL MARKET · COAG
-2.77% · -$1.36 · Vol 215.2K
Live · updated 15:35:40 ET
Hemab Therapeutics Holdings Inc

Hemab Therapeutics Holdings Inc

Biotechnology
$47.80
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Valuation absence reason unknown · Earnings absence reason unknown
COAG
Hemab Therapeutics Holdings Inc
Fri Aug 21 · last completed session · daily score · 2d 21h old
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · daily score · 2d 21h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is COAG moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading COAG catalysts
About Hemab Therapeutics Holdings Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2026
Country
US

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$49.10
Day high
$50.15
Day low
$46.59
Previous close
$49.16
52W high
$54.94
-13.00% from high
52W low
$24.98
76% of range
Market cap
$2.3B
EPS
$-3.2000
Beta
1.43
Shares out
46.7M
Volume
215.2K
0.55× rel vol
Avg volume
388.2K
VWAP
$47.81
Price history computed in-house
1W
-10.80%
1M
+1.04%
3M
+71.70%
SMA 50 $41.51 · above
SMA 200 Not reported · Not reported
52W position 76%

COAG overview

Veridion Score
55
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around COAG.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading COAG Form 4 filings
Public disclosures

Congress activity in COAG

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for COAG in the cached public ledger.

Federal contracts

COAG contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for COAG in this window.
Lobbying spend

COAG lobbying filings, year to date.

Registered lobbying filings matched to Hemab Therapeutics Holdings Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for COAG in this window.
Loading news for COAG
Analyst ratings
Sovereign unlock shows live analyst consensus for COAG.
Options
Sovereign unlock shows live options positioning for COAG.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.